ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

NPIL, Lilly Form Another R&D Pact

February 25, 2008 | APPEARED IN VOLUME 86, ISSUE 8

Mumbai-based Nicholas Piramal India Ltd. and Eli Lilly & Co. have reached a second drug discovery agreement. NPIL and Lilly will separately conduct early clinical development on different drug candidates directed at the same biological target. NPIL stands to gain as much as $110 million in milestones and royalties if the program is successful. Last year, NPIL licensed a Lilly compound in order to conduct preclinical and clinical studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment